Metrika gets US nod for HbA1c test:
This article was originally published in Clinica
Executive Summary
Diagnostic firm Metrika has been given the green light to market in the US its point-of-care A1cNow INView multi-test system for monitoring levels of HbA1c, the current gold standard for diabetes control. Used in a doctor's office or at home, the pager-sized device provides laboratory-quality results in five minutes from a 10 microlitre finger prick sample. Doctors can then determine a patient's average blood sugar level over the previous 2-3 months, the Sunnyvale, California firm claims. Studies show that a 1% reduction in HbA1C can lower the risk of blindness, amputation, kidney and nerve disease by 40%. Metrika will introduce the system later this year.
You may also be interested in...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.